Avalo Therapeutics (AVTX) Accumulated Expenses (2014 - 2026)

Avalo Therapeutics has reported Accumulated Expenses for 13 years, with the latest figure at $327000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 92.85% year-over-year to $327000.0; the trailing twelve-month figure through Mar 2026 stood at $327000.0 (down 92.85% YoY), and the FY2025 full-year result was $2.0 million, up 511.62% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $327000.0, down from $2.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $14.1 million in Q1 2022, with the low at $214000.0 in Q3 2023.
• Historically, Accumulated Expenses has averaged $3.6 million across 5 years, with a median of $2.0 million in 2022.
• Annual changes were most pronounced in 2023 — Accumulated Expenses tumbled 95.41% — and 2024, when it soared 3186.45%.
• Avalo Therapeutics' Accumulated Expenses stood at $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then tumbled by 83.65% to $327000.0 in 2024, then jumped by 511.62% to $2.0 million in 2025, then tumbled by 83.65% to $327000.0 in 2026.
• The last three Accumulated Expenses figures came in at $327000.0 (Q1 2026), $2.0 million (Q4 2025), and $327000.0 (Q3 2025), per Business Quant data.